CD80 anticorps (Extracellular Domain)
Aperçu rapide pour CD80 anticorps (Extracellular Domain) (ABIN6992239)
Antigène
Voir toutes CD80 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Épitope
- Extracellular Domain
-
Purification
- CD80 Antibody is supplied as protein A purified IgG2b.
-
Immunogène
- CD80 antibody was raised against the extracellular domain of human CD80.
-
Isotype
- IgG2b
-
-
-
-
Indications d'application
-
CD80 antibody can be used for immunohistochemistry starting at 2 - 5 μ,g/mL. For immunofluorescence start at 5 μ,g/mL. Flow cytometry at 10 μ,g/mL.
Antibody validated: Immunohistochemistry in human samples, Immunocytochemistry in human samples, Immunofluorescence in human samples and Flow Cytometry in mouse samples. All other applications and species not yet tested. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- CD80 Antibody is supplied in PBS containing 0.02 % sodium azide and 50 % glycerol.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C,4 °C
-
Stockage commentaire
- CD80 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
-
-
- CD80
-
Autre désignation
- CD80
-
Sujet
- CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).
-
Poids moléculaire
-
Predicted: 32 kDa
Observed: 50 kDa -
ID gène
- 941
-
NCBI Accession
- NP_005182
-
UniProt
- P33681
-
Pathways
- TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
Antigène
-